Investors Overview

Corporate Profile
Cipher Pharmaceuticals is a growing specialty pharmaceutical dermatology company, with a robust and diversified portfolio of commercial and early to late-stage products. Through multiple transactions, Cipher has built its U.S. commercial presence, expanded its Canadian dermatology franchise and broadened its pipeline. Cipher is well-capitalized to drive long-term, sustained earnings growth by leveraging its proven clinical development capabilities and efficient commercial execution.

CIPHER PHARMACEUTICALS ANNOUNCES PLANS TO VOLUNTARILY DELIST FROM NASDAQ

ExchangeTSX (Canadian Dollar)
PriceCan$4.50
Change (%) Stock is Down 0.05 (1.10%)
Volume5,150
Data as of 02/24/17 3:59 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle 
02/16/17Notice of Cipher Pharmaceuticals Inc. Q4 and Year-End 2016 Conference CallPrinter Friendly Version
11/29/16Cipher Pharmaceuticals Announces Plans to Voluntarily Delist from NASDAQPrinter Friendly Version
11/11/16Cipher Pharmaceuticals Reports Q3 2016 Financial ResultsPrinter Friendly Version
Featured Documents
Download Documentation Investor Presentation - Q3 2016
Download Documentation Q3 Report
Download Documentation Q2 Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Cipher Pharmaceuticals Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources